In a leaked ab­stract, J&J's cell ther­a­py ap­pears to have dra­mat­ic ben­e­fits for mul­ti­ple myelo­ma pa­tients

Pa­tients tak­ing Leg­end Biotech and John­son & John­son’s can­cer cell ther­a­py Carvyk­ti had a 74% re­duc­tion in the risk of mul­ti­ple myelo­ma pro­gres­sion or death …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.